Solasia Pharma KK (JP:4597) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Solasia Pharma K.K. has revised its earnings forecast for 2024, anticipating a significant decrease in revenue due to sluggish product shipments and delays in out-licensing DARVIAS® in China. The company now expects an operating loss of 1,150 million yen, driven by reduced revenue expectations and lower R&D and SG&A expenses. Solasia remains focused on finalizing licensing agreements for DARVIAS® in China and other regions as a priority.
For further insights into JP:4597 stock, check out TipRanks’ Stock Analysis page.